폐섬유증 바이오마커 시장 : 시장 규모, 점유율, 동향 및 성장 분석 보고서(2026-2034년)

The global pulmonary fibrosis biomarkers market size is expected to reach USD 7.61 Billion in 2034 from USD 4.95 Billion in 2025, growing at a CAGR of 4.89 during 2026-2034.This market is experiencing significant growth driven by the increasing prevalence of pulmonary fibrosis and the need for early and accurate diagnosis. Biomarkers play a crucial role in identifying disease progression, monitoring treatment response, and improving patient outcomes. The growing focus on personalized medicine and targeted therapies is significantly contributing to the expansion of this market. Advances in molecular biology and diagnostic technologies are enabling the discovery of new biomarkers, further supporting market growth.

Key drivers include rising healthcare awareness, increasing investments in research and development, and advancements in diagnostic techniques. Healthcare providers are increasingly adopting biomarker-based tests to improve diagnostic accuracy and reduce treatment delays. The expansion of clinical trials and collaborations between research institutions and pharmaceutical companies are accelerating the development of novel biomarkers. Additionally, the growing aging population is contributing to the rising incidence of pulmonary diseases.

Future prospects for this market remain highly promising, with continuous innovation in biomarker discovery and validation. The integration of artificial intelligence and data analytics will enhance diagnostic capabilities and enable more precise treatment planning. Emerging markets are expected to offer significant growth opportunities due to improving healthcare infrastructure. As the focus on early diagnosis and personalized treatment continues to grow, the pulmonary fibrosis biomarkers market is poised for sustained expansion.

Our reports are carefully developed to deliver comprehensive and actionable insights across a wide range of industries and markets. Each report includes several essential components designed to provide a complete understanding of the market environment:

Market Overview: This section provides a clear introduction to the market, including key definitions, classifications, and an overview of the current industry landscape.

Market Dynamics: A detailed evaluation of the primary drivers, restraints, opportunities, and challenges shaping market growth. It covers factors such as technological developments, regulatory frameworks, and evolving industry trends.

Segmentation Analysis: A structured breakdown of the market into key segments based on product type, application, end-user, and geographic region. This section highlights the performance, growth potential, and contribution of each segment.

Competitive Landscape: An in-depth assessment of leading market participants, including their market positioning, product portfolios, strategic initiatives, and financial performance. It provides valuable insights into competitive dynamics and the strategies adopted by key players.

Market Forecast: Data-driven projections of market size and growth patterns over a defined forecast period. This section incorporates historical trends, current market conditions, and quantitative analysis to illustrate expected future developments.

Regional Analysis: A comprehensive review of market performance across major geographic regions, identifying high-growth areas and regional trends to better understand localized market opportunities.

Emerging Trends and Opportunities: Identification of significant market trends, technological advancements, and new investment opportunities. This section highlights potential growth areas and future industry developments.

Customization Options: We offer flexible customization services to tailor reports according to specific client requirements. This may include additional segmentation, country-level analysis, competitor profiling, customized data points, or focused insights on particular market segments to better support strategic decision-making.

MARKET SEGMENTATION

By Test Type

• Blood Test
• Pulmonary Function Test
• Imaging Test
• Lung Biopsy
• Other Test Types

By Indication

• Idiopathic Pulmonary Fibrosis (IPF)
• Rheumatoid Arthritis Interstitial Lung Disease (RA-ILD)
• Drug-Induced Pulmonary Fibrosis
• COVID-19-Related Pulmonary Fibrosis
• Pneumoconiosis
• Sarcoidosis
• Other Indications

By End-user

• Hospitals
• Specialty Clinics
• Diagnostic Laboratories
• Research & Academic Institutes
• Other End-Users

COMPANIES PROFILED

• Biocartis NV, Biogen Inc., Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd, Galapagos NV, Lung Therapeutics Inc., Myriad Genetics Inc., OptiKira LLC, Respivant Sciences GmbH, Veracyte Inc.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL PULMONARY FIBROSIS BIOMARKERS MARKET: BY TEST TYPE 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Test Type
• 4.2. Blood Test Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Pulmonary Function Test Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Imaging Test Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Lung Biopsy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.6. Other Test Types Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL PULMONARY FIBROSIS BIOMARKERS MARKET: BY INDICATION 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Indication
• 5.2. Idiopathic Pulmonary Fibrosis (IPF) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Rheumatoid Arthritis Interstitial Lung Disease (RA-ILD)

Estimates and Forecasts By Regions 2022-2034 (USD MN)

• 5.4. Drug-Induced Pulmonary Fibrosis Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. COVID-19-Related Pulmonary Fibrosis Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.6. Pneumoconiosis Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.7. Sarcoidosis Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.8. Other Indications Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL PULMONARY FIBROSIS BIOMARKERS MARKET: BY END-USER 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast End-user
• 6.2. Hospitals Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Specialty Clinics Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Diagnostic Laboratories Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.5. Research & Academic Institutes Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.6. Other End-Users Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL PULMONARY FIBROSIS BIOMARKERS MARKET: BY REGION 2022-2034 (USD MN)

• 7.1. Regional Outlook
• 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.2.1 By Test Type
  • 7.2.2 By Indication
  • 7.2.3 By End-user
  • 7.2.4 United States
  • 7.2.5 Canada
  • 7.2.6 Mexico
• 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.3.1 By Test Type
  • 7.3.2 By Indication
  • 7.3.3 By End-user
  • 7.3.4 United Kingdom
  • 7.3.5 France
  • 7.3.6 Germany
  • 7.3.7 Italy
  • 7.3.8 Russia
  • 7.3.9 Rest Of Europe
• 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.4.1 By Test Type
  • 7.4.2 By Indication
  • 7.4.3 By End-user
  • 7.4.4 India
  • 7.4.5 Japan
  • 7.4.6 South Korea
  • 7.4.7 Australia
  • 7.4.8 South East Asia
  • 7.4.9 Rest Of Asia Pacific
• 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.5.1 By Test Type
  • 7.5.2 By Indication
  • 7.5.3 By End-user
  • 7.5.4 Brazil
  • 7.5.5 Argentina
  • 7.5.6 Peru
  • 7.5.7 Chile
  • 7.5.8 Rest of Latin America
• 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.6.1 By Test Type
  • 7.6.2 By Indication
  • 7.6.3 By End-user
  • 7.6.4 Saudi Arabia
  • 7.6.5 UAE
  • 7.6.6 Israel
  • 7.6.7 South Africa
  • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

• 8.1. Recent Developments
• 8.2. Company Categorization
• 8.3. Supply Chain & Channel Partners (based on availability)
• 8.4. Market Share & Positioning Analysis (based on availability)
• 8.5. Vendor Landscape (based on availability)
• 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL PULMONARY FIBROSIS BIOMARKERS INDUSTRY

• 9.1. Top Companies Market Share Analysis
• 9.2. Company Profiles
  • 9.2.1 Biocartis NV
  • 9.2.2 Biogen Inc
  • 9.2.3 Bristol-Myers Squibb Company
  • 9.2.4 F. Hoffmann-La Roche Ltd
  • 9.2.5 Galapagos NV
  • 9.2.6 Lung Therapeutics Inc
  • 9.2.7 Myriad Genetics Inc
  • 9.2.8 OptiKira LLC
  • 9.2.9 Respivant Sciences GmbH
  • 9.2.10 Veracyte Inc